Alumis Inc Stock News

Alumis shares sink after the California-based biotech says envudeucitinib failed to meet the primary endpoint of a mid-stage trial.

Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in ​a smaller subset of patients, even after the treatment failed ‌to meet the main goal of a mid-stage trial.

– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high) support moving forward with Phase 3 development in SLE – – Pharmacodynamic data substantiate envudeucitinib's potential in interferon-driven immune-mediated diseases – – Envudeucitinib was ge...

– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –